RxDoctor Payments Data

Alpana Jayadevan, NP

Nurse Practitioner · Cumming, GANPI 1386277036

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $16,742 of the $24,653 with a category attached, or 67.9%. It is spread thinly across 30 manufacturers, the largest accounting for just 23.7%. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,653in general payments, 2019–2025

Across 805 payments — averaging $30.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Novartis$5K
  • Amgen$3K
  • UCB, Inc.$2K
  • Johnson & Johnson$1K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $6K from 24 others

What the payments were for

  • Consulting fees$6,80828%
  • Travel & lodging$7003%
  • Food & beverage$16,74268%
  • Education$4032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,653 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$4,847
Medicare patients
41
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$164,707
Cosentyx Sensoready (2 Pens)Secukinumab19$136,373
ProliaDenosumab15$25,112
Hydroxychloroquine Sulfate150$4,503
Febuxostat17$2,024
Duloxetine Hcl145$1,926
Leflunomide63$1,807
MethotrexateMethotrexate Sodium76$1,521
Prednisone223$1,109
Gabapentin79$880
Allopurinol41$663
Pregabalin28$657
Celecoxib34$376
Venlafaxine Hcl ErVenlafaxine Hcl46$295
Methylprednisolone13$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$2,764$25,11215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →